Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

Prognostic Role of Pre-Treatment Carcinoembryonic Antigen and Carbonhydrate Antigen 19-9 in Metastatic Colorectal Cancer

Pages
73–80
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The parameters evaluated were age, gender, tumor location, metastatic organs, resection of the primary tumor, metastasectomy, pretreatment serum concentrations of CEA and CA19-9,first line chemotherapy regimens and overall survival (OS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Carcinoembrionic Antigen (CEA) and carbohydrateantigen 19-9 (CA 19-9) are the most commonly usedtumor-associated antigens in the colorectal cancer.
📊
Key Findings & Data:Several contradictory studies reported that patients with metastatic colorectal cancer (mCRC) with normal serum CEA and CA 19-9 levels survived significantly longer than patientswith higher serum CEA and CA19-9 levels.Methods: 240 patients with mCRC were enrolled.
💡
Conclusion & Impact:The parameters evaluated were age, gender, tumor location, metastatic organs, resection of the primary tumor, metastasectomy, pretreatment serum concentrations of CEA and CA19-9,first line chemotherapy regimens and overall survival (OS).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Carcinoembrionic Antigen (CEA) and carbohydrateantigen 19-9 (CA 19-9) are the most commonly usedtumor-associated antigens in the colorectal cancer. Several contradictory studies reported that patients with metastatic colorectal cancer (mCRC) with normal serum CEA and CA 19-9 levels survived significantly longer than patientswith higher serum CEA and CA19-9 levels.Methods: 240 patients with mCRC were enrolled. The parameters evaluated were age, gender, tumor location, metastatic organs, resection of the primary tumor, metastasectomy, pretreatment serum concentrations of CEA and CA19-9,first line chemotherapy regimens and overall survival (OS). CEA and CA19-9 were divided into three groups as normal(CEA ≤5 ng/mL, CA 19-9 ≤35 U/mL) elavated (CEA: 5–50 ng/mL, CA19-9:35–350 U/mL) and high (CEA >50 ng/mL, andCA 19-9 >350 U/mL). Primary study endpoint was overall survival (OS).Results: Serum CA 19-9 level (p=0.040), primary tumor resection (p

🔖

Cite This Article

URVAY, S., KARAGÖZ, H. (2022). Prognostic Role of Pre-Treatment Carcinoembryonic Antigen and Carbonhydrate Antigen 19-9 in Metastatic Colorectal Cancer. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 73–80. https://ajindex.com/articles/508603

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34
  3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108
  4. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104–17
  5. Hashizume R, Kawahara H, Ogawa M, Suwa K, Eto K, Yanaga K. CA19-9 concentration after first-line chemotherapy ıs prognostic predictor of metastatic colon cancer. In Vivo 2019;33:2087–93
  6. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004;240:644–57
  7. Hidaka E, Maeda C, Nakahara K, Wakamura K, Ishiyama Y, Shimada S, et al. High serum CA19-9 concentration predicts poor prognosis in elderly patients with stage IV colorectal cancer. Gastrointest Tumors 2019;5:117–24
  8. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007;14:786–94
  9. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263–7
  10. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 2016;17:1709–19
  11. Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, et al. Japanese society of medical oncology clinical guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. Cancer Sci 2015;106:324–7
  12. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 201